Hussein N Yassine1, Alexandra Belopolskaya2, Christina Schall3, Craig S Stump4, Serrine S Lau5, Peter D Reaven6. 1. University of Southern California, Los Angeles, CA. Electronic address: hyassine@usc.edu. 2. University of Southern California, Los Angeles, CA. 3. University of Arizona, Tucson, AZ. 4. University of Arizona, Tucson, AZ; Southern Arizona VA Health Care Systems, Tucson, AZ. 5. University of Arizona, Tucson, AZ; Southwest Environmental Health Sciences Center, Tucson, AZ. 6. Phoenix VA Health Care System, Phoenix, AZ.
Abstract
OBJECTIVE: Our objective was to examine the role of hypertriglyceridemia on the capacity of HDL to facilitate ABCA-1 mediated cholesterol efflux in type 2 diabetes (T2DM). METHODS: HDL mediated cholesterol efflux through the ABCA-1 transporter was measured using BHK cell lines in samples of 71 participants with T2DM in the presence or absence of high triglyceride levels (TG). Additionally, HDL mediated efflux was measured in 13 diabetic and non-diabetic participants fasting and four hours after a high-fat test challenge. RESULTS: HDL mediated cholesterol efflux function was increased in participants with T2DM with hypertriglyceridemia when compared to participants with T2DM without hypertriglyceridemia (efflux ratio mean±standard deviation (SD), T2DM+TG: 1.17±0.25 vs. T2DM - TG: 1.03±0.19, p=0.0098). In the fat challenge study, we observed a significant increase in ABCA-1 mediated cholesterol efflux capacity following an ingestion of high-fat test meal by participants in both groups of T2DM (n=6, efflux ratio, mean±SD, pre: 0.86±0.4 vs. post: 1.34±0.6, p=0.01) and non-diabetic participants (n=7, efflux ratio mean±SD pre: 1.24±0.31 vs. post: 1.39±0.42, p=0.04) that was partly explained by the difference in CETP activity (r=0.6, p=0.03). CONCLUSION: Our study suggests that high triglyceride levels facilitate ABCA-1 mediated efflux function of HDL in part by activating CETP.
OBJECTIVE: Our objective was to examine the role of hypertriglyceridemia on the capacity of HDL to facilitate ABCA-1 mediated cholesterol efflux in type 2 diabetes (T2DM). METHODS: HDL mediated cholesterol efflux through the ABCA-1 transporter was measured using BHK cell lines in samples of 71 participants with T2DM in the presence or absence of high triglyceride levels (TG). Additionally, HDL mediated efflux was measured in 13 diabetic and non-diabeticparticipants fasting and four hours after a high-fat test challenge. RESULTS: HDL mediated cholesterol efflux function was increased in participants with T2DM with hypertriglyceridemia when compared to participants with T2DM without hypertriglyceridemia (efflux ratio mean±standard deviation (SD), T2DM+TG: 1.17±0.25 vs. T2DM - TG: 1.03±0.19, p=0.0098). In the fat challenge study, we observed a significant increase in ABCA-1 mediated cholesterol efflux capacity following an ingestion of high-fat test meal by participants in both groups of T2DM (n=6, efflux ratio, mean±SD, pre: 0.86±0.4 vs. post: 1.34±0.6, p=0.01) and non-diabeticparticipants (n=7, efflux ratio mean±SD pre: 1.24±0.31 vs. post: 1.39±0.42, p=0.04) that was partly explained by the difference in CETP activity (r=0.6, p=0.03). CONCLUSION: Our study suggests that high triglyceride levels facilitate ABCA-1 mediated efflux function of HDL in part by activating CETP.
Authors: Bela F Asztalos; Margarita de la Llera-Moya; Gerard E Dallal; Katalin V Horvath; Ernst J Schaefer; George H Rothblat Journal: J Lipid Res Date: 2005-08-01 Impact factor: 5.922
Authors: Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat Journal: Arterioscler Thromb Vasc Biol Date: 2010-01-14 Impact factor: 8.311
Authors: Anatol Kontush; Patrice Therond; Amal Zerrad; Martine Couturier; Anne Négre-Salvayre; Juliana A de Souza; Sandrine Chantepie; M John Chapman Journal: Arterioscler Thromb Vasc Biol Date: 2007-06-14 Impact factor: 8.311
Authors: Jia Long; Chan-Juan Zhang; Neng Zhu; Ke Du; Yu-Fang Yin; Xi Tan; Duan-Fang Liao; Li Qin Journal: Am J Cancer Res Date: 2018-05-01 Impact factor: 6.166
Authors: Tatjana Josefs; Kristiaan Wouters; Uwe J F Tietge; Wijtske Annema; Robin P F Dullaart; Tomas Vaisar; Ilja C W Arts; Carla J H van der Kallen; Coen D A Stehouwer; Casper G Schalkwijk; Ira J Goldberg; Edward A Fisher; Marleen M J van Greevenbroek Journal: J Clin Lipidol Date: 2019-10-31 Impact factor: 4.766
Authors: Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov Journal: Am J Physiol Endocrinol Metab Date: 2019-09-10 Impact factor: 4.310
Authors: Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow Journal: J Clin Lipidol Date: 2020-11-24 Impact factor: 4.766
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Marleen M J van Greevenbroek; Carla J H van der Kallen; Casper G Schalkwijk; Coen D A Stehouwer; Robin P F Dullaart; Uwe J F Tietge Journal: Sci Rep Date: 2016-06-08 Impact factor: 4.379
Authors: Marilia C O Sprandel; Whady A Hueb; Alexandre Segre; José A F Ramires; Roberto Kalil-Filho; Raul C Maranhão Journal: Cardiovasc Diabetol Date: 2015-08-14 Impact factor: 9.951